2021
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach C, Kahl B, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke J, Hirata J, Jiang Y, Paulson J, Chang Y, Musick L, Abrisqueta P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet Haematology 2021, 8: e891-e901. PMID: 34826412, DOI: 10.1016/s2352-3026(21)00311-2.Peer-Reviewed Original ResearchConceptsRecommended phase 2 doseRefractory follicular lymphomaPhase 2 dosePolatuzumab vedotinFollicular lymphomaAdverse eventsDay 1Dose escalationResponse rateRefractory diffuse large B-cell lymphomaCohort 3Treatment due to disease progressionCohort 2Diffuse large B-cell lymphomaEastern Cooperative Oncology Group performance statusCycles of induction treatmentDose-limiting toxicity eventsLarge B-cell lymphomaTyrosine kinase inhibitor treatmentComponent drugsPhase 1b/2 studyPhase 1b/2 trialComplete response rateDose-escalation phaseDose-limiting toxicity
2020
Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA
Herrera A, Tracy S, Croft B, Opat S, Ray J, Musick L, Paulson J, Sehn L, Jiang Y. Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA. Blood 2020, 136: 23-25. DOI: 10.1182/blood-2020-136645.Peer-Reviewed Original ResearchProgression-free survivalCirculating tumor DNACurrent equity holderInternational Prognostic IndexEntity's Board of DirectorsDetect circulating tumor DNABaseline ctDNA levelCtDNA levelsOverall survivalR/R DLBCLHazard ratioPrognostic factorsHigh riskTumor DNARefractory diffuse large B-cell lymphomaDiffuse large B-cell lymphoma patientsDiffuse large B-cell lymphomaMeasuring circulating tumor DNASource of germline DNACirculating tumor DNA levelsB-cell lymphoma patientsLarge B-cell lymphomaLactate dehydrogenaseEarly identification of patientsFirst-line setting
2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M, Assouline S, Kim T, Kim W, Ozcan M, Hirata J, Penuel E, Paulson J, Cheng J, Ku G, Matasar M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal Of Clinical Oncology 2019, 38: 155-165. PMID: 31693429, PMCID: PMC7032881, DOI: 10.1200/jco.19.00172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalSurvival RateConceptsProgression-free survivalLarge B-cell lymphomaPolatuzumab vedotinB-cell lymphomaCR rateOverall survivalPola-BRR/R DLBCLRefractory diffuse large B-cell lymphomaIRC-assessed progression-free survivalDiffuse large B-cell lymphomaB-cell receptor componentsSingle-arm cohortsDuration of responseCohort of patientsCox regression methodRisk of deathMedian OSSafety profileKaplan-MeierTreatment optionsB cellsPolatuzumabBendamustineDLBCL